FDA rejects Ocular Therapeutix eye drug, citing manufacturing issues
by Adam Feuerstein
Jul 11, 2017
1 minute
Ocular Therapeutix failed for a second time to secure approval of its eye drug Dextenza. On Tuesday, the FDA rejected the
You’re reading a preview, subscribe to read more.
Start your free 30 days